

# Linda R Duska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6643952/publications.pdf>

Version: 2024-02-01

46  
papers

1,056  
citations

567281

15  
h-index

434195

31  
g-index

48  
all docs

48  
docs citations

48  
times ranked

1882  
citing authors

#	ARTICLE	IF	CITATIONS
1	Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. , 2022, 10, e004233.		24
2	Society of Gynecologic Oncology recommendations for fellowship education during the COVID-19 pandemic and beyond: Innovating programs to optimize trainee success. Gynecologic Oncology, 2021, 160, 271-278.	1.4	4
3	A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clinical Cancer Research, 2021, 27, 2734-2741.	7.0	7
4	Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecologic Oncology, 2021, 161, 512-515.	1.4	4
5	A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecologic Oncology, 2020, 156, 13-22.	1.4	9
6	Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia. American Journal of Surgical Pathology, 2020, 44, 1184-1191.	3.7	18
7	Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer, 2020, 126, 4948-4956.	4.1	37
8	Validation of the surprise question in gynecologic oncology: A one-question screen to promote palliative care integration and advance care planning.. Gynecologic Oncology, 2020, 157, 754-758.	1.4	13
9	Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 957-968.	10.7	140
10	Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia. Modern Pathology, 2020, 33, 1182-1192.	5.5	28
11	Are ethnic and racial minority women less likely to participate in clinical trials?. Gynecologic Oncology, 2020, 157, 323-328.	1.4	27
12	The role of pulmonary resection in the management of metastatic gestational trophoblastic neoplasia: Two cases of durable remission following surgery for chemo-resistant disease. Gynecologic Oncology Reports, 2019, 30, 100496.	0.6	1
13	Cancer Screening and Prevention Highlights in Gynecologic Cancer. Obstetrics and Gynecology Clinics of North America, 2019, 46, 19-36.	1.9	11
14	Emerging biomarkers in ovarian granulosa cell tumors. International Journal of Gynecological Cancer, 2019, 29, 560-565.	2.5	13
15	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clinical Cancer Research, 2019, 25, 2450-2457.	7.0	52
16	A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 473-482.	2.3	7
17	Opioid use in gynecologic oncology in the age of the opioid epidemic: Part I - Effective opioid use across clinical settings, a society of gynecologic oncology evidence-based review. Gynecologic Oncology, 2018, 149, 394-400.	1.4	10
18	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report. Gynecologic Oncology, 2018, 149, 442-446.	1.4	14

#	ARTICLE	IF	CITATIONS
19	Opioid use in gynecologic oncology in the age of the opioid epidemic: Part II – Balancing safety & accessibility. <i>Gynecologic Oncology</i> , 2018, 149, 401-409.	1.4	7
20	Targeted Therapies and Immunotherapy for Gynecologic Malignancies: Living Longer, Living Better With Noncytotoxic Options in Recurrent Disease. <i>Clinical Therapeutics</i> , 2018, 40, 358-360.	2.5	2
21	Access to quality gynecologic oncology care: A work in progress. <i>Cancer</i> , 2018, 124, 2680-2683.	4.1	4
22	Cervical cancer care in rural Virginia: The impact of distance from an academic medical center on outcomes & the role of non-specialized radiation centers. <i>Gynecologic Oncology</i> , 2018, 150, 338-342.	1.4	13
23	A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule ROR1 <sup>3</sup> agonist to treat select solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS2617-TPS2617.	1.6	0
24	Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). <i>Cancer</i> , 2017, 123, 977-984.	4.1	31
25	Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. <i>Gynecologic Oncology</i> , 2017, 146, 34-38.	1.4	27
26	Cutting costs and standardizing care: Once-per-cycle complete blood count monitoring may be safe for patients undergoing platinum-based chemotherapy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 758-762.	1.3	1
27	Opioid Use in Gynecologic Oncology; Balancing Efficacy, Accessibility and Safety: An SGO Clinical Practice Statement. <i>Gynecologic Oncology</i> , 2017, 144, 232-234.	1.4	15
28	Prospective screening with the validated Opioid Risk Tool demonstrates gynecologic oncology patients are at low risk for opioid misuse. <i>Gynecologic Oncology</i> , 2017, 147, 456-459.	1.4	16
29	Strategies for Introducing Outpatient Specialty Palliative Care in Gynecologic Oncology. <i>Journal of Oncology Practice</i> , 2017, 13, e712-e720.	2.5	21
30	Treatment of Older Women With Endometrial Cancer: Improving Outcomes With Personalized Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 164-174.	3.8	10
31	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
32	Cervical Cancer: The Next Generation of Prevention, Detection, and Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 446-448.	2.5	3
33	Fertility-Sparing Options for Early Cervical Cancer: Optimism for Oncologic and Obstetric Outcomes. <i>Current Obstetrics and Gynecology Reports</i> , 2016, 5, 296-306.	0.8	1
34	Does one size fit all? The updated ovarian cancer staging: Still a work in progress. <i>Cancer</i> , 2015, 121, 3384-3386.	4.1	0
35	Severe Gastrointestinal Complications in the Era of Image-guided High-dose-rate Intracavitary Brachytherapy for Cervical Cancer. <i>Clinical Therapeutics</i> , 2015, 37, 49-60.	2.5	9
36	Preoperative imaging of uterine malignancy: A low-value service. <i>Gynecologic Oncology</i> , 2015, 137, 285-290.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Uterine carcinosarcoma: A review of the literature. <i>Gynecologic Oncology</i> , 2015, 137, 581-588.	1.4	167
38	Nutrition in Gynecologic Cancer. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 265-271.	0.8	4
39	Lean methodology improves efficiency in outpatient academic Gynecologic Oncology clinics. <i>Gynecologic Oncology</i> , 2015, 138, 707-711.	1.4	27
40	Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). <i>Gynecologic Oncology</i> , 2015, 139, 221-227.	1.4	20
41	Improving quality of life in female cancer survivors: current status and future questions. <i>Future Oncology</i> , 2014, 10, 1015-1026.	2.4	4
42	A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 44-48.	1.4	16
43	Histologic Effects of Medroxyprogesterone Acetate on Endometrioid Endometrial Adenocarcinoma. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 543-553.	1.4	34
44	The Patient Protection and Affordable Care Act: What every provider of Gynecologic Oncology care should know. <i>Gynecologic Oncology</i> , 2013, 129, 606-612.	1.4	2
45	Prevention of human papillomavirus-related malignancy: Access is the answer. <i>Cancer</i> , 2013, 119, 2953-2955.	4.1	1
46	When "never-events" occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. <i>Gynecologic Oncology</i> , 2010, 116, 374-377.	1.4	111